Oral anticoagulant therapy for six months provided no benefit over six weeks for preventing recurrent venous thromboembolism in patients without a history of VTE or continuing predisposing cause.
RCT (n=186)
In the past, there has been no agreement as to the desirable duration of oral anticoagulant therapy for patients after venous thromboembolism. A randomized trial, in which patients were treated for six weeks or six months after diagnosis, was established to clarify the situation. A total of 186 patients were studied. The results suggest that there is no benefit from oral anticoagulants administered for longer than six weeks, unless there is a past history of venous thromboembolism, a recurrent thrombotic tendency or a continuing predisposing cause. Adequate heparinization is of prime importance in the early management of these patients. Abrupt cessation of oral anticoagulant therapy did not increase the incidence of recurrent venous thromboembolism. Bleeding complications are minimized if careful control is observed, and if drug interactions are avoided when other therapy is required for patients on oral anticoagulant therapy.
E. F. O'Sullivan (Wed,) conducted a rct in Venous thromboembolism (n=186). Oral anticoagulant therapy for six months vs. Oral anticoagulant therapy for six weeks was evaluated on Recurrent venous thromboembolism. Oral anticoagulant therapy for six months provided no benefit over six weeks for preventing recurrent venous thromboembolism in patients without a history of VTE or continuing predisposing cause.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: